Summary G1147211 is a novel. totally synthetic camptothecin with promising preclinical and early clinical activity. This study was designed to determine the maximum tolerated dose of Gl147211 as a 72-h infusion and to describe its pharmacokinetics and pharmacodynamics on this schedule. In a single-arm, rising-dose study in patients with advanced cancer, eight cohorts of three or more patients received 72-h infusions of G1147211 at doses ranging from 0.25 to 2.5 mg m-2 day-'. Forty-four patients received a total of 124 cycles. All patients had refractory tumours and 40 had received prior chemotherapy and/or radiotherapy. Whole-blood G1147211 lactone, total blood and total concentrations were measured during and over the 12 h following the infusion. Myelosuppression was observed at all dose levels. Neutropenia was dose limiting at 2.0 mg m-2 day-' in minimally pretreated patients, while both neutropenia and thrombocytopenia were limiting at 1.5 mg m-2 day-' in those more heavily pretreated. Phlebitis occurred with infusions through peripheral veins early in this study, necessitating the use of central venous access. Other toxicities included mild nausea and vomiting, fatigue, headache, central venous catheter infections and alopecia. Three partial and two minor responses lasting 8-34+ weeks were noted in patients with ovarian, colon and breast carcinomas and hepatoma. Mean steady-state concentrations of G1147211 increased with dose over a range of 0.25-1.24 ng ml'. The mean terminal elimination hatf-life was 7.5 h. and the clearance averaged 1074 ml min-' m-2 over the doses studied. The mean fractional excretion of unchanged drug in urine was 0.1 14. Gi147211 lactone exposure correlated with haematological toxicity. The recommended phase II doses for this regimen are 1.75 mg m-2 day-' and 1.2 mg m-2 day-' for minimally pretreated and heavily pretreated patients respectively. At these doses, steady-state G1147211 concentrations within the range of those effective in vitro were achieved. Extensive phase 11 evaluation of this compound and further phase trials evaluating more prolonged infusions are ongoing.
Keywords: G1147211: GG211: camptothecin analogues: topoisomerase inhibitor; phase trial; pharmacokinetics: pharmacodynamics: continuous infusion GI 147211 (7-4 methyl piperazinomethilene)-10.1 1 -ethylenedioxy-20-(S camptothecin: Figure 1 ) is a totally synthetic analogue of camptothecin. a natural product isolated from Camptotheca acuminata (WAall et al. 1966 : Emerson et al. 1995 . Despite the sicrnificant anti-tumour actixvity of the parent compound camptothecin in preclinical models and in early clinical trials. its further development >-as compromised by severe and unpredictable toxicitv involxino the bone marrow. gastrointestinal tract and urothelium (Gottlieb et al. 1970 : Mluggia et al. 1972 ). In part. the insolubility of camptothecin x-as central to this undesirable adx erse picture. The nuclear enzyvme DNA topoisomerase I. x hich relaxes DNA supercoils arising during, replication and gene transcription. has been identified as the specific targret of camptothecin (Hsianer and Liu. 1988: Wall and Wani. 1995) . The mechanism of cytotoxicity of camptothecin (and of its analogues) involves the formation of a coxalent complex Awith topoisomerase I and DNA: this cleavable complex stabilizes DNA single strand break-s. xwhich mav be converted to double strand break-s upon encountering a replication fork (Zhang et al. 1990 : Slichenmver et al. 1993 . Topoisomerase I enzN-me lexels in cancer cell lines and in surmical specimens of a range of human tumours are higher than those of normal tissues (Giovanella et al. 1989 : Husain et al. 1994 . These findings stimulated the clinical evaluation of less toxic. watersoluble analogues of camptothecin. The semisy nthetic derivatives topotecan and irinotecan (CPT-l1b has-e rood preclinical antitumour activitx. reproducible toxicitv in earlx clinical trials and encouraging activitv in several human tumours (Slichenmver et al. 1993; Potmesil. 1994: Wall and W'ani. 1995) .
GI 14721 1 is a whollv synthetic camptothecin analogue in w-hich molecular modifications have been made to enhance w-ater solubilitv and to increase affinity for topoisomerase I. As w-ith all camptothecin analogues. GI14721 actixvity against a broad range of cell lines. In vixo studies usinr, colon (HT29 and SW480). breast (MX 1). oxarian (SKOV3). prostate (PC3) and lung (H460) carcinoma xenografts in nude mice confirmed the anti-tumour actixitv (Emerson et al. 1986 (Emerson et al. . 1993 (Emerson et al. . 1994 (Emerson et al. . 1995 x ere continued on therapy. (Miller et al. 1981 (coeffecient of variation < 10%7). The mobile phase consists of 25%7 acetonitrile and 10% ammonium acetate buffer pumped at 1.7 ml rmm'n. The internal standard used in this assav is 6.7-dimethoxy-4-methylcoumnarin (Stafford and St Claire. 1995) .
Pharmacokinetic analysis
Plasma G11472 11 concentration vs time curves wxere evaluated using model-independent methods (Gibaldi. 1984 subjects. The mean fraction of drug excreted unchanged in the urine (fe) was 0.114 ± 0.041 and the renal clearance averaged 164 ± 61 ml min-across the doses measured.
Pharnacodynamics
The CSS of the GI147211 lactone correlated with the decrease in neutrophil and platelet counts using the sigmoid E model ( Figure 4A and B). While variability was high. a steep concentration-response curve was observed between 0.5 and 1.5 ng ml-l.
Based on this model. neutrophils were more sensitive than platelets to G1147211 toxicity. The half-maximal concentration was 0.75 ng ml-1 for the fonner and 1.4 ng ml-1 for the latter. While the ability of the bone marrow to recover from GI147211 is an important factor. it may be observed from Table 2 that prior treatment alone is insufficient to account for the wide variability in toxicity at a particular dose level (see, for example. the 2 mg m-' day-' dose level). Nor do differences in drug exposure explain the variability: as may be observed in Figure 4 . a broad range of toxicity outlines the characteristic sigmoidal curve. The steep concentration-response curve is characteristic of this class of drug (Grochow et al. 1992 : Haas et al. 1994 and emphasizes the need to understand the pharmacodynamic basis of drug effect. In vitro studies of cell lines with varying topoisomerase I content suggest that the expression of topoisomerase I may be a detenrninant of camptothecin effect: the higher the topoisomerase I expression the more sensitive the cell line to camptothecin-induced cytotoxicity (Pommier et al. 1994) . However. Pommier et al (1994) have shown that topoisomerase I activity alone does not explain varying sensitivity. In peripheral mononuclear cells from patients undergoing treatment with the topoisomerase I inhibitor topotecan. the opposite relationship has been found: those expressing lower topoisomerase I levels had more myelotoxicity (Khater et al. 1995) . Clearly, a simple explanation for the variable toxicity is not yet evident and additional pharmacodynamic studies are needed.
The modest incidence of non-haematological toxicity makes GI14721 1 an excellent candidate for combination with other drugs or radiation therapy. Mild and easily preventable emesis and shortlasting fatigue were the main complaints. In contrast to irinotecan. G1147211 does not induce diarrhoea (Slichenmyer et al. 1993; Potmesil. 1994 : Abigerges et al. 1995 . This may relate to the fact that G1147211 is the active compound. while irinotecan is a prodrug which is converted to SN-38. the active metabolite. An important site of this conversion appears to be the intestinal mucosa. in which high levels of SN-38 may be formed locally. with attendant mucosal damage (Gupta et al. 1994) . The lack of gastrointestinal toxicity of G1147211 doubtless accounted for the infrequent finding of sepsis. even in the face of profound neutropenia. Also remarkable is the absence of mucositis in the Phase I study of Gl147211 as 72-h infusion 1335 present study. Only one episode of grade IH stomatitis was seen. and this occurred at 2.5 mg m-2 day-'. concomitantly with neutropenic fever. By contrast. mucositis was dose limiting in a 5-day infusion phase I study of topotecan in leukaemic patients (Kantarjian et al. 1993) . The absence of urothelial toxicity is similar to topotecan and is probably due to improved water solubility (Emerson et al. 1995) . The propensity of GI147211 to induce phlebitis at venepuncture sites with infusion times of less than 24 h makes the use of central vein catheters a prerequisite for protracted administration schedules.
Anti-tumour activity was documented in five patients with colon. ovary and breast cancers and hepatoma. These three partial and two minor responses are particularly noteworthy as they occurred in patients who had been previously treated with conventional chemotherapy. This. coupled with the significant antiproliferative activity of GI 147211 in preclinical models in breast. colon and ovarian tumours (Emerson et al. 1995) . and the anti-tumour activity seen with the daily x 5-day regimen. justifies further phase II evaluation GI14721 1. Except for the partial response in the patient with ovarian cancer observed at 0.5 mg m-2 day-'. all other tumour regressions appeared at higher dose levels (1.5-2.0 mg inday-'). suggesting a dose-response relationship. This high rate of response was also identified in another GI14721 1 phase I trial and these data suggest that the drug may have useful activity when used in a population with less advanced disease.
Pharmacokinetic studies showed that Css was related to dose but there was a two-to threefold variation in Css with dose level. Css at doses 2 1.2 mg m-2 day-' were above 1 ng mF' which are potentially cytotoxic (e.g. 50% growth inhibition concentration for the melanoma cell line Lox was 0.592 ng ml-') (Emerson et al. 1995) .
The Css of topotecan lactone at MTD of 1.6 mg m-2 day-' administered as a continuous infusion for 3 days every 3 weeks was 5.5 ng ml-l (Burris et al. 1994). These differences in drug levels at doses that produce similar degrees of myelosuppression may be accounted for by topotecan being measured from plasma and G1147211 from whole blood. and the observation that the latter compound is 2-5 times more active in in vitro models (Slichenmyer et al. 1993 : Emerson et al. 1995 . It remains to be seen if this enhanced potency of GI 14721 1 will translate to a selective advantage in clinical trials.
The terminal half-life (7.5 h) in the present study was higher than that observed after 30 min infusions. possibly reflecting the absence of tissue distribution which has already occurred during the 72-h infusion period. Better characterization of the elimination of the carboxylate would be achieved with later sampling points. From these data. the slower clearance of the carboxylate form (mean terminal half-life 20 h) may also provide a source of continuing formation of lactone during the elimination phase. Although greater interpatient variability was observed, the average clearance increased with increasing dose. particularly at doses > 1.0 mg m-' day-'. These data do not support a definitive conclusion. but ratelimited elimination or binding processes may be operating at higher doses. As the major route of metabolism of the lactone is its conversion to the open ring acid form. it is unlikely that the compound induces its own metabolism. In this study. approximately 11% of total GI 147211 was recovered unaltered in urine.
confirming animal data that biliary and/or intestinal excretion are the main routes of elimination for this drug.
In summary. myelosuppression is the DLT of GI147211 as a 72-h infusion every 3 weeks. Haematological toxicity was doserelated. non-cumulative. reversible and dependent on the extent of prior chemotherapy. Central venous catheters are required as prolonged infusions induce phlebitis. At the recommended doses for phase II trials (1.75 mg m-2 day-' and 1.2 mg m-2 day-' for untreated/minimally treated and heavily pretreated patients respectively). the schedule is well tolerated in an outpatient basis with minimal non-haematological toxicity and promising evidence of anti-tumour activity. The anti-tumour activity documented in this trial supports a broad phase II evaluation of this drug. which is now in progress using the five daily dose schedule. In attempting to optimize the therapeutic efficacy of GI1472 11. the duration of tumour exposure to the drug may be increased by prolonging the infusion time or by oral administration. For this reason. phase I trials testing 14-and 21-day infusions every 4-5 weeks and a bioavailability study of an oral formulation of the compound have been started.
